Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hepatocellular Carcinoma: early-phase trial registry
65 of 146 indexed Hepatocellular Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #80 of 28,707 conditions by registered trial count.
146 US clinical trials · 65 currently recruiting · #80 of 28,707 conditions by registered trial count
Hepatocellular Carcinoma: 146 US clinical trials tracked, 65 recruiting.
Hepatocellular Carcinoma is the subject of 146 registered US clinical trials on ClinicalTrials.gov, 65 of them currently open to new participants. 20 are in Phase 3-4 (later-stage) and 92 in Phase 1-2 (earlier-stage). The most active sponsor is AstraZeneca, running 8 of these trials.
Enrollment posture brief
Registry condition hepatocellular-carcinoma
OPEN 65 | RECR 45% | LATE 20 | EARLY 92 | RANK #80 | SPON 8
Volume-matched condition peers
Nearest open-share peer: Critical Illness (45% recruiting · 92 trials)
Hepatocellular Carcinoma lists 65 open slots (45% of 146 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hepatocellular Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hepatocellular Carcinoma is recruiting above its size-band peers.
65 of 146 indexed trials (44.5%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Hepatocellular Carcinoma trials is spread across many organizations.
AstraZeneca accounts for 8 of 146 trials (5.5%). 94 distinct sponsors appear on at least one study for this condition label.
-
Typical Hepatocellular Carcinoma enrolment sits around 70 participants.
Median target enrolment is 70 among the 146 trials that report a genuine target (sentinel values excluded). 82 of those (56.2%) plan for fewer than 100 participants.
-
Hepatocellular Carcinoma research is mostly interventional.
129 interventional and 17 observational studies make up this index (88.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
146 total, page 2 of 3
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Teclison
NCT02174549
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria
The Methodist Hospital Research Institute
NCT05185505
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
Baylor College of Medicine
NCT06198296
Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
Seattle Children's Hospital
NCT07148050
Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment
University of Tennessee
NCT03686709
Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab
University of California, San Diego
NCT06710223
T-Cell Therapy (ECT204) in Adults With Advanced HCC
Eureka Therapeutics
NCT04864054
SIRT With Tremelimumab and Durvalumab for Resectable HCC
Jiping Wang, MD, PhD
NCT05701488
Evaluating Novel Therapies in ctDNA Positive GI Cancers
Georgetown University
NCT05482516
A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma
University of Michigan Rogel Cancer Center
NCT05901519
The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)
Inova Health Care Services
NCT06789757
SBRT With Atezo/Bev for HCC
Abramson Cancer Center at Penn Medicine
NCT05488522
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
University of California, Irvine
NCT05497531
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
Inova Health Care Services
NCT06007846
AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma
University of Florida
NCT05669339
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
Exact Sciences Corporation
NCT05064553
Extracellular RNA Markers of Liver Disease and Cancer
Mayo Clinic
NCT02908048
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
AstraZeneca
NCT03298451
Registry 17-009: Multi-Institutional Study Examining Patients With HCC Undergoing Liver Transplantation
Federico Aucejo
NCT06018857
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Exelixis
NCT03170960
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
AstraZeneca
NCT03847428
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
Exelixis
NCT03755791
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
AstraZeneca
NCT05301842
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
Bristol-Myers Squibb
NCT04039607
A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma
AstraZeneca
NCT03778957
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
Hoffmann-La Roche
NCT05904886
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
Bristol-Myers Squibb
NCT03383458
A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma
CStone Pharmaceuticals
NCT04194775
A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma
MedImmune
NCT02519348
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
AbbVie
NCT06084481
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
ImmunoVaccine Technologies, Inc. (IMV Inc.)
NCT03836352
Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)
AbbVie
NCT05822752
Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)
ABK Biomedical
NCT05953337
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
National Cancer Institute (NCI)
NCT02867592
TheraSphere With Durvalumab and Tremelimumab for HCC
Boston Scientific Corporation
NCT05063565
Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions
M.D. Anderson Cancer Center
NCT02156739
A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma
AstraZeneca
NCT06084884
Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients
Regeneron Pharmaceuticals
NCT03916627
Domvanalimab and Zimberelimab in Advanced Liver Cancers
University of Texas Southwestern Medical Center
NCT05724563
Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis
National Cancer Institute (NCI)
NCT02968810
Neoadjuvant Nivolumab with CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)
Icahn School of Medicine at Mount Sinai
NCT04123379
The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy
HistoSonics
NCT04572633
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
Northwestern University
NCT04550481
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio
NCT03228667
TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients
Abramson Cancer Center at Penn Medicine
NCT01918683
Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function
M.D. Anderson Cancer Center
NCT02626312
A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma
David Hsieh
NCT03519997
DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection
National Cancer Institute (NCI)
NCT02772003
Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT04658147
Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
Davendra Sohal
NCT05027425
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 47 |
| Phase 2 | 45 |
| Phase 3 | 17 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Hepatocellular Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hepatocellular Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hepatocellular Carcinoma page
146 registered trials, 65 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 65 Hepatocellular Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- AstraZeneca sponsors the most Hepatocellular Carcinoma trials on record, review their full trial history before evaluating a specific study. See AstraZeneca's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hepatocellular Carcinoma condition card totals 146 registered trials; most-linked intervention Bevacizumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.